Jump to content

Cinacalcet: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Addbot (talk | contribs)
Bots
2,838,809 edits
m Bot: Migrating 3 interwiki links, now provided by Wikidata on d:q193978 (Report Errors)
fix dead link
Line 74: Line 74:
*[http://www.sensipar.com/ Sensipar website] run by [[Amgen]]
*[http://www.sensipar.com/ Sensipar website] run by [[Amgen]]
*[http://www.sensipar.com/pdf/sensipar_pi.pdf Prescribing information (package insert)]
*[http://www.sensipar.com/pdf/sensipar_pi.pdf Prescribing information (package insert)]
*[http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/500521.html Cinacalcet] - Medlineplus.org
*[http://www.nlm.nih.gov/medlineplus/druginfo/meds/a605004.html Cinacalcet] - Medlineplus.org
*[http://www.drugdigest.org/DD/DVH/Uses/0,3915,8207%7CCinacalcet,00.html Cinacalcet] - Drug Digest.
*[http://www.drugdigest.org/DD/DVH/Uses/0,3915,8207%7CCinacalcet,00.html Cinacalcet] - Drug Digest.
{{Calcium homeostasis}}
{{Calcium homeostasis}}

Revision as of 06:14, 6 March 2013

Cinacalcet
Clinical data
AHFS/Drugs.comMonograph
MedlinePlusa605004
License data
Pregnancy
category
  • AU: B3
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability20 to 25%
Increases if taken with food
Protein binding93 to 97%
MetabolismHepatic (CYP3A4-, CYP2D6- and CYP1A2-mediated)
Elimination half-life30 to 40 hours
ExcretionRenal (80%) and fecal (15%)
Identifiers
  • (R)-N-[1-(1-naphthyl)ethyl]-3-
    [3-(trifluoromethyl)phenyl]propan-1-amine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.208.116 Edit this at Wikidata
Chemical and physical data
FormulaC22H22F3N
Molar mass357.412 g/mol g·mol−1
3D model (JSmol)
  • FC(F)(F)c1cccc(c1)CCCN[C@@H](c3c2ccccc2ccc3)C
  • InChI=1S/C22H22F3N/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3/t16-/m1/s1 checkY
  • Key:VDHAWDNDOKGFTD-MRXNPFEDSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Cinacalcet (INN) is a drug that acts as a calcimimetic (i.e. it mimics the action of calcium on tissues) by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues. It is sold by Amgen under the trade name Sensipar in North America and Australia and as Mimpara in Europe. Cinacalcet is used to treat secondary hyperparathyroidism (elevated parathyroid hormone levels), a consequence of having end-stage renal disease.[1] Cinacalcet is also indicated for the treatment of hypercalcemia in patients with parathyroid carcinoma.[2]

Clinical trials conducted in the United States by Amgen to determine whether the drug is safe for children were halted by the FDA in February 2013 following the death of a 14-year-old patient.[3]

Clinical uses

Cinacalcet is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis and hypercalcemia in patients with parathyroid carcinoma.

Synthesis

B.C. Van Wagenen, S.T. Moe, M.F. Balandrin, E.G. DelMar, E.F. Nemeth, U.S. patent 6,211,244 (2001).

References

  1. ^ Torres PU (2006). "Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease". Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation. 16 (3): 253–8. doi:10.1053/j.jrn.2006.04.010. PMID 16825031.
  2. ^ "Sensipar for Parathyroid Carcinoma". Amgen. 2009. Retrieved 25 September 2009.
  3. ^ Edney, Anna (February 26, 2013). "Amgen Pediatric Trials of Sensipar Halted by FDA After Death". Businessweek.
Stub icon

This hormonal preparation article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Cinacalcet&oldid=542332278"